Zimmer Biomet (NYSE and SIX: ZBH) today launched WalkAI, artificial intelligence that can predict which patients will have lower gait speed 90 days after hip or knee surgery.
WalkAI is part of ZBEdge, Zimmer Biomet’s suite of integrated smart, digital and robotic technologies to boost patient outcomes after orthopedic surgeries.
The proprietary algorithm behind WalkAI analyzes a person’s mobility to generate a personalized daily prediction of their gait (walking) speed at 90 days after surgery. The daily predictions draw on extensive, anonymized, real-world data in the ZBEdge database.
“WalkAI is built from our wealth of anonymized ZBEdge data and is the first model to demonstrate our unique capability to deliver actionable predictions by connecting real-world data and AI through ZBEdge products and experiences,” said Liane Teplitsky, president of Global Robotics and Technology & Data Solutions at Zimmer Biomet.
The AI works with ZB’s MyMobility care management platform, which collects gait data through patients’ iPhones patient gait data. Then, when needed, it can notify health professionals through the MyMobility clinician dashboard.
Zimmer Biomet has rolled out WalkAI to a select group of MyMobility users. It will be widely available as part of ZBEdge by the end of the month.
“Our strategic prioritization and investment in R&D has solidified our position as an innovator in our space with breakthrough technologies like Persona IQ, a first-to-world smart knee implant, MyMobility care management platform, Rosa robotics, and now, WalkAI, the first AI-based model in orthopedics to create daily personalized outcome predictions based on a patient’s gait recovery,” said Zimmer Biomet COO Ivan Tornos.